Aberdeen Group plc Sells 41,436 Shares of Tempus AI, Inc. $TEM

Key Points

• Aberdeen Group plc reduced its stake in Tempus AI, Inc. by 16.3%, selling 41,436 shares, and now holds 213,294 shares valued at approximately $13.6 million.
• After reporting a quarterly earnings per share of ($0.22), Tempus AI's revenue increased by 89.5% year-over-year, reaching $314.64 million, surpassing analyst expectations.
• Several institutional investors have recently increased their positions in Tempus AI, including ARK Investment Management, which boosted its stake by 35.9%, now owning over 7.5 million shares.

Aberdeen Group plc reduced its stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 16.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 213,294 shares of the company's stock after selling 41,436 shares during the quarter. Aberdeen Group plc owned about 0.12% of Tempus AI worth $13,553,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. ARK Investment Management LLC boosted its position in shares of Tempus AI by 35.9% in the 1st quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock worth $361,867,000 after purchasing an additional 1,981,755 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Tempus AI by 6,247.5% during the 1st quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock valued at $289,204,000 after buying an additional 5,900,668 shares during the period. Nikko Asset Management Americas Inc. lifted its holdings in shares of Tempus AI by 31.5% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock valued at $205,401,000 after buying an additional 1,021,460 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Tempus AI by 31.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock valued at $205,284,000 after buying an additional 1,016,384 shares during the period. Finally, CloudAlpha Capital Management Limited Hong Kong bought a new position in shares of Tempus AI during the 1st quarter valued at $34,119,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Trading Down 4.9%

NASDAQ:TEM opened at $89.87 on Wednesday. The company has a debt-to-equity ratio of 2.58, a current ratio of 1.54 and a quick ratio of 1.43. The firm has a market capitalization of $15.61 billion, a price-to-earnings ratio of -75.52 and a beta of 4.87. Tempus AI, Inc. has a one year low of $31.36 and a one year high of $104.32. The business has a fifty day moving average price of $80.27 and a 200-day moving average price of $65.36.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The business had revenue of $314.64 million during the quarter, compared to analyst estimates of $296.84 million. During the same quarter in the prior year, the business posted ($6.86) EPS. Tempus AI's revenue for the quarter was up 89.5% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TEM. Bank of America increased their price target on Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a report on Wednesday, June 25th. Needham & Company LLC restated a "buy" rating and issued a $70.00 price objective on shares of Tempus AI in a research note on Friday, August 8th. BTIG Research upped their price objective on Tempus AI from $75.00 to $85.00 and gave the stock a "buy" rating in a research note on Wednesday, August 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Tempus AI in a research note on Wednesday, October 8th. Finally, HC Wainwright upped their price objective on Tempus AI from $90.00 to $98.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $71.83.

Insiders Place Their Bets

In other Tempus AI news, COO Ryan Fukushima sold 5,000 shares of the stock in a transaction on Monday, October 6th. The stock was sold at an average price of $92.32, for a total value of $461,600.00. Following the completion of the sale, the chief operating officer owned 130,000 shares in the company, valued at approximately $12,001,600. This represents a 3.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James William Rogers sold 7,528 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $561,965.20. Following the completion of the sale, the chief financial officer owned 138,473 shares of the company's stock, valued at $10,337,009.45. The trade was a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 933,662 shares of company stock worth $68,070,993 in the last three months. 26.27% of the stock is owned by company insiders.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.